Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and Neurology (NCT03526809) | Clinical Trial Compass
UnknownNot Applicable
Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and Neurology
United Kingdom40 participantsStarted 2016-06-01
Plain-language summary
Patients with known ovarian cancer will be imaged up to four times with FDG-PET, C13 MRI and other novel MRI techniques during their treatment course including: before the start of any treatment (with optional repeat scanning), after the first dose of chemotherapy (optional), after the third dose of chemotherapy (optional) and after surgery (optional). Imaging findings will be compared to biological properties of cancer tissue samples.
Who can participate
Age range
18 Years – 99 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Be 18 years or older.
. Have a confirmed or likely diagnosis of HGSOC, breast cancer, prostate cancer, pancreatic mass, liver mass, renal mass or brain tumour.
. Be aware of their diagnosis.
. Be a likely surgical candidate who is fit for possible surgery.
. Have no contraindications to the use of the IV contrast agents involved in this study.
. Be able to provide written informed consent according to ICH/GCP, national and local regulations.
. Volunteers of childbearing potential must have a negative pregnancy test, either urinary or blood prior to enrolment.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Imaging of the metabolism of hyperpolarized 13C-pyruvate in ovarian cancer tissue to hyperpolarized 13C-lactate.
Timeframe: 1 July 2016 to 31 December 2018
Trial details
NCT IDNCT03526809
SponsorCambridge University Hospitals NHS Foundation Trust
. Any disorder that may adversely affect levels of pyruvate or lactate such as diabetes mellitus.
. The use of medications that may affect levels of pyruvate or lactate such as metformin or insulin.
. Known allergy or adverse reaction to any of the injected contrast agents proposed for use in this study.
. Pregnancy or breastfeeding.
. Other severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or in the judgement of the investigators make it undesirable for the patient to enter the study.
. Laboratory abnormalities that may have an unknown or unpredictable impact on study results.
. Not suitable for MR scanning e.g. severe obesity, inability to lie still or contraindicated metal implants such as the intrauterine contraceptive device.